Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 7/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | PDE1A | P54750 | 1/20 | 0.64 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.64 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 8/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778223 | 1.00 | PSMB1 (0.70) | PSMB1PSMB5PSMB2HRH3ESR1 | |
| SCHEMBL4517043 | 0.98 | PSMB1 (0.67) | PSMB1PSMB5PSMB2HRH3ESR1 | |
| SCHEMBL2819407 | 0.91 | HRH3 (0.75) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL737990 | 0.91 | HRH3 (0.75) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL12834986 | 0.90 | HRH3 (0.73) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL73562 | 0.89 | HRH3 (0.72) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL16358313 | 0.88 | HRH3 (0.71) | HRH3PDE1APDE1BPDE1C | |
| SCHEMBL3578646 | 0.85 | HRH3 (0.90) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL17197058 | 0.83 | DRD3 (0.52) | PSMB1PSMB5PSMB2HRH3ESR1 | |
| SCHEMBL3562722 | 0.83 | NPC1 (0.66) | HRH3LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812417-B1 | NOVEL 2H-CHROMENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-29 | — | — | EP | disclosed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| EP-1812417-A1 | NOVEL 2H-CHROMENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-01 | — | — | EP | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| US-20060166933-A1 | Novel 2H-chromene derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006055694-A1 | NOVEL 2H-CHROMENE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-26 | — | — | WO | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1569939-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004050660-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166933-A1 | Novel 2H-chromene derivatives as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | PSMB1 1851/4885PSMB5 1337/4885PSMB2 1156/4885 |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PSMB1 1278/4885PSMB5 833/4885PSMB2 1340/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PSMB1 1278/4885PSMB5 833/4885PSMB2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.